Dianthus Therapeutics (DNTH) Non-Current Deferred Tax Liability (2017 - 2022)
Dianthus Therapeutics (DNTH) posted quarterly Non-Current Deferred Tax Liability of $949000.0 for Q4 2022, down 18.26% year-over-year from $1.2 million in Q4 2021, and down 18.26% quarter-over-quarter from $1.2 million in Q4 2021.
Dianthus Therapeutics (DNTH) Non-Current Deferred Tax Liability (2017 - 2022) Analysis & Trends
Dianthus Therapeutics' Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $949000.0 for Q4 2022.
- In Q4 2022, Non-Current Deferred Tax Liability fell 18.26% year-over-year to $949000.0; the TTM figure through Dec 2022 stood at $949000.0 (down 18.26% YoY), while the FY2022 annual figure was $949000.0, down 18.26% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2022 stood at $949000.0, down from $1.2 million in the prior quarter.
- The five-year high for Non-Current Deferred Tax Liability was $1.2 million in Q4 2021, with the low at $361000.0 in Q4 2018.
- The 3-year median for Non-Current Deferred Tax Liability is $949000.0 (2022), against an average of $823666.7.
- The sharpest annual moves came in 2018 and 2022: Non-Current Deferred Tax Liability soared 684.78% in 2018, then dropped 18.26% in 2022.
- Dianthus Therapeutics' Non-Current Deferred Tax Liability stood at $361000.0 in 2018, then soared by 221.61% to $1.2 million in 2021, then retreated by 18.26% to $949000.0 in 2022.
- Business Quant data shows DNTH's Non-Current Deferred Tax Liability at $949000.0 in Q4 2022, $1.2 million in Q4 2021, and $361000.0 in Q4 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 949,000.00 |
| Dec 31, 2022 | 949,000.00 |
| Dec 31, 2021 | 1.16 Mn |
| Dec 31, 2021 | 1.16 Mn |
| Dec 31, 2018 | 361,000.00 |
| Dec 31, 2018 | 361,000.00 |
| Dec 31, 2017 | 46,000.00 |
| Dec 31, 2017 | 46,000.00 |